Clinical experience of melagatran/ximelagatran in major orthopaedic surgery

Thrombosis Research

Volumn 109, Issue SUPPL., 2003, Pages

  Eriksson, Bengt I ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Melagatran; Orthopaedic surgery; Thrombin inhibitor; Venous thromboembolism; Ximelagatran

Indexed keywords

AZETIDINE DERIVATIVE; DALTEPARIN; DRUG DERIVATIVE; ENOXAPARIN; GLYCINE; LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; XIMELAGATRAN;

BLEEDING; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG SCREENING; HIP ARTHROPLASTY; HUMAN; METHODOLOGY; ORTHOPEDIC SURGERY; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; THROMBOEMBOLISM; THROMBOSIS; TOTAL KNEE REPLACEMENT; TREATMENT OUTCOME;

EID: 0038006773     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(03)00248-2     Document Type: Conference Paper

References (14)

1. Kakkar V.V. Prevention and management of venous thrombosis. Br. Med. Bull. 50:1994;871-903.
2. Geerts W.H., Heit J.A., Clagett G.P., Pineo G.F., Colwell C.W., Anderson F.A. Jr.et al. Prevention of venous thromboembolism. Chest. 119:2001;132S-175S.
3. Collins R., Scrimgeour A., Yusuf S., Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. N. Engl. J. Med. 318:1988;1162-1173.
4. Eriksson U.G., Johansson L., Frison L., Bredberg U., Gustafsson D. Single and repeated oral dosing of H 376/95, a prodrug of the direct thrombin inhibitor melagatran, to young healthy male subjects. Blood. 94(Suppl. 1):1999;26a. [Abstract No. 101].
5. Eriksson-Lepkowska M., Thuresson A., Bylock A., Frison L., Eriksson U.G. The effect of the oral direct thrombin inhibitor, ximelagatran (pINN, formerly H 376/95), on the pharmacokinetics and pharmacodynamics of diclofenac in healthy male volunteers. Thromb. Haemost. 2001 (July);. [Suppl. (ISSN 0340-6245). Abstract No. P786].
6. Eriksson-Lepkowska M., Thuresson A., Bylock A., Frison L., Eriksson U.G. The effect of the oral direct thrombin inhibitor, ximelagatran (pINN, formerly H 376/95), on the pharmacokinetics of diazepam in healthy male volunteers. Thromb. Haemost. 2001 (July);. [Suppl. (ISSN 0340-6245). Abstract No. P785].
7. Johansson S., Bylock A., Eriksson-Lepkowska M., Thuresson A., Frison L., Eriksson U.G. The effect of the oral direct thrombin inhibitor, ximelagatran (pINN, formerly H 376/95), on the pharmacokinetics of nifedipine in healthy male volunteers. Thromb. Haemost. 2001 (July);. [Suppl. (ISSN 0340-6245). Abstract No. P784].
8. Elg M., Gustafsson D., Carlsson S. Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat. Thromb. Res. 94:1999;187-197.
9. Bredberg U., Eriksson U.G., Taure K., Johansson L., Frison L., Gustafsson D. Effects of melagatran, a novel direct thrombin inhibitor, in healthy volunteers following intravenous, subcutaneous and oral administration. Blood. 94(Suppl. 1):1999;28a. [Abstract No. 110].
10. Eriksson U.G., Frison L., Gustafsson D., Mandema J., Karlsson M.O., Eriksson B. Pharmacokinetics of melagatran, the active form of the oral, direct thrombin inhibitor H 376/95, in orthopaedic surgery patients treated to prevent deep vein thrombosis and pulmonary embolism. Blood. 96:2000;93b. [Abstract No. 4087].
11. Eriksson B.I., Arfwidsson A.-C., Frison L., Eriksson U.G., Bylock A., Kälebo P.et al. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery. Thromb. Haemost. 87:2002;231-237.
12. Biello D.R., Mattar A.G., McKnight R.C., Siegel B.A. Ventilation-perfusion studies in suspected pulmonary embolism. Am. J. Roentgenol. 133:1979;1033-1037.
13. Eriksson B.I., Ekman S., Kälebo P., Zachrisson B., Bach D., Close P. Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393. Lancet. 347:1996;635-639.
14. Eriksson B.I., Wille-Jorgensen P., Kälebo P., Mouret P., Rosencher N., Bosch P.et al. A comparison of recombinant hirudin with low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N. Engl. J. Med. 337:1997;1329-1335.